ACM
PCRX icon

AlphaCrest Capital Management’s Pacira BioSciences PCRX Stock Holding History

AlphaCrest Capital Management’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-7,724
Closed -$411K – 830
2022
Q3 		$411K Buy
7,724
+1,093
+16% +$60.8K 0.03% 1052
2022
Q2 		$387K Buy
+6,631
New +$434K 0.02% 1033
2022
Q1 		– Sell
-11,465
Closed -$690K – 1365
2021
Q4 		$690K Buy
11,465
+1,203
+12% +$66.3K 0.03% 962
2021
Q3 		$575K Sell
10,262
-7,237
-41% -$417K 0.03% 857
2021
Q2 		$1.06M Buy
+17,499
New +$1.11M 0.05% 639
2021
Q1 		– Sell
-16,173
Closed -$968K – 1273
2020
Q4 		$968K Buy
16,173
+12,759
+374% +$747K 0.08% 331
2020
Q3 		$205K Sell
3,414
-1,456
-30% -$84.6K 0.02% 1030
2020
Q2 		$256K Buy
+4,870
New +$204K 0.04% 707
2020
Q1 		– Sell
-11,599
Closed -$525K – 1211
2019
Q4 		$525K Sell
11,599
-14,838
-56% -$630K 0.04% 758
2019
Q3 		$1.01M Buy
26,437
+3,095
+13% +$124K 0.06% 567
2019
Q2 		$1.01M Buy
23,342
+6,002
+35% +$255K 0.09% 390
2019
Q1 		$660K Buy
17,340
+8,440
+95% +$329K 0.1% 348
2018
Q4 		$383K Buy
+8,900
New +$415K 0.11% 346

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $7.3B AUM 41.96% 1-Year Est. Return

AlphaCrest Capital Management's PCRX Position: Q4 2022 in Review

AlphaCrest Capital Management sold out of Pacira BioSciences (PCRX) in Q4 2022, closing a stake of 7,724 shares — an estimated $411K sold.

AlphaCrest Capital Management first reported a position in PCRX in Q4 2018 and held it in 13 quarters. The position peaked at $1.06M in Q2 2021. 273 funds tracked by Wall St. Rank hold PCRX as of Q4 2022.

  • AlphaCrest Capital Management reported no remaining Pacira BioSciences position as of Q4 2022 after selling out during the quarter.
  • AlphaCrest Capital Management sold 7,724 Pacira BioSciences shares in Q4 2022, an estimated $411K.
  • AlphaCrest Capital Management first reported a position in Pacira BioSciences in Q4 2018 and held it in 13 quarters.
  • AlphaCrest Capital Management's Pacira BioSciences position peaked at $1.06M in Q2 2021.
  • 273 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2022.

Based on AlphaCrest Capital Management's 13F filing for Q4 2022.